Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyteir Therapeutics Inc
(NQ:
CYT
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
3.070 (100)
Ask (Size)
3.140 (105)
Prev. Close
3.020
Today's Range
N/A - N/A
52wk Range
2.720 - 3.190
Shares Outstanding
71,281,616
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
March 07, 2024
From
Cyteir Therapeutics
Via
Business Wire
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
October 12, 2023
From
Cyteir Therapeutics
Via
Business Wire
Performance
More News
Read More
Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher
June 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
June 30, 2023
Via
Benzinga
Cyteir Therapeutics (NASDAQ: CYT) to Dissolve After Discontinuing Development of CYT-0851
June 30, 2023
Via
Spotlight Growth
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 30, 2023
Via
Benzinga
Crude Oil Rises Over 1%; Fed's Preferred Inflation Gauge Slows In May
June 30, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
June 30, 2023
Via
Benzinga
Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution
June 30, 2023
From
Cyteir Therapeutics
Via
Business Wire
Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile
June 03, 2023
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights
May 10, 2023
From
Cyteir Therapeutics, Inc.
Via
Business Wire
Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
March 23, 2023
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer
February 06, 2023
From
Cyteir Therapeutics
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway
January 19, 2023
From
Cyteir Therapeutics
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023
January 20, 2023
Via
Benzinga
Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights
November 07, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium
October 12, 2022
From
Cyteir Therapeutics
Via
Business Wire
5 Value Stocks In The Healthcare Sector
September 12, 2022
Via
Benzinga
Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
August 31, 2022
From
Cyteir Therapeutics
Via
Business Wire
Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights
August 08, 2022
From
Cyteir Therapeutics
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Via
Benzinga
Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
August 01, 2022
From
Cyteir Therapeutics
Via
Business Wire
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
July 27, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit